The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Natalizumab for Active Crohn's Disease
Abstract
BACKGROUND: In chronic inflammatory conditions such as Crohn's disease, the migration of leukocytes from the circulation into the parenchyma and their activation within inflammatory sites are mediated in part by alpha4 integrins. METHODS: We conducted a double-blind, placebo-controlled trial of the alpha4 integrin-specific humanized monoclonal antibody natalizumab in 248 patients with moderate-to-severe Crohn's disease. Patients were randomly assigned to receive one of four treatments: two infusions of placebo; one infusion of 3 mg of natalizumab per kilogram of body weight, followed by placebo; two infusions of 3 mg of natalizumab per kilogram; or two infusions of 6 mg of natalizumab per kilogram. Infusions were given four weeks apart. Outcomes included changes in scores for the Crohn's Disease Activity Index (higher scores indicate more severe disease), the health-related quality of life, and C-reactive protein levels. RESULTS: The group given two infusions of 6 mg of natalizumab per kilogram did not have a significantly higher rate of clinical remission (defined by a score of less than 150 on the Crohn's Disease Activity Index) than the placebo group at week 6 (the prospectively defined primary end point in the efficacy analysis). However, both groups that received two infusions of natalizumab had higher remission rates than the placebo group at multiple time points. Natalizumab also produced a significant improvement in response rates (defined by a reduction of at least 70 points in the score on the Crohn's Disease Activity Index). The highest remission rate was 44 percent and the highest response rate was 71 percent (at week 6 in the group given two infusions of 3 mg per kilogram). Overall, the two infusions of 6 mg of natalizumab per kilogram and of 3 mg per kilogram had similar effects. The quality of life improved in all natalizumab groups; C-reactive protein levels improved in groups receiving two infusions of natalizumab. The rates of adverse events were similar in all four groups. CONCLUSIONS: Treatment with the selective adhesion-molecule inhibitor natalizumab increased the rates of clinical remission and response, improved the quality of life and C-reactive protein levels, and was well tolerated in patients with active Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
Springer, T. A. (1994) · Cell · doi:10.1016/0092-8674(94)90337-9 · Cited by 6,929
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Unbalanced Repeated-Measures Models with Structured Covariance Matrices
Jennrich, R. I., & Schluchter, M. D. (1986) · Biometrics · doi:10.2307/2530695 · Cited by 1,325
Endothelial-Leukocyte Adhesion Molecules
Bevilacqua, M. P. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.004003 · Cited by 1,293
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Irvine, E. J., Feagan, B., Rochon, J., Archambault, A., Fedorak, R. N., Groll, A., Kinnear, D., Saibil, F., & McDonald, J. W. D. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90585-1 · Cited by 712
Landis, J. R., Heyman, E. R., & Koch, G. G. (1978) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402373 · Cited by 454
Cited by
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Self-citationAbraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
The immunological and genetic basis of inflammatory bowel disease
Bouma, G., & Strober, W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1132 · Cited by 1,767
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,757
Immune cell migration in inflammation: present and future therapeutic targets
Luster, A. D., Alon, R., & von Andrian, U. H. (2005) · Nature Immunology · doi:10.1038/ni1275 · Cited by 1,313
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Self-citationNatalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Self-citationEosinophilic gastrointestinal disorders (EGID)
Rothenberg, M. E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.047 · Cited by 923
Therapeutic strategies for rheumatoid arthritis
Smolen, J. S., & Steiner, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1109 · Cited by 911
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Self-citationTargeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 701
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Ren, G., Zhao, X., Zhang, L., Zhang, J., L'Huillier, A., Ling, W., Roberts, A. I., Le, A. D., Shi, S., Shao, C., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902023 · Cited by 656
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Self-citationEfficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.73 · Cited by 604
Chemokines and Their Receptors: Drug Targets in Immunity and Inflammation
Viola, A., & Luster, A. D. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.121806.154841 · Cited by 583
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy
HEBBEL, R. P., OSAROGIAGBON, R., & KAUL, D. (2004) · Microcirculation · doi:10.1080/10739680490278402 · Cited by 463
Soler, D., Chapman, T., Yang, L.-L., Wyant, T., Egan, R., & Fedyk, E. R. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153973 · Cited by 456
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Self-citationIntegrin-based therapeutics: biological basis, clinical use and new drugs
Ley, K., Rivera-Nieves, J., Sandborn, W. J., & Shattil, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.10 · Cited by 403
Myers, G. L., Rifai, N., Tracy, R. P., Roberts, W. L., Alexander, R. W., Biasucci, L. M., Catravas, J. D., Cole, T. G., Cooper, G. R., Khan, B. V., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148980.87579.5e · Cited by 391
Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G. K., Peyrin-Biroulet, L., & Danese, S. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.039 · Cited by 387
G Protein-Coupled Receptor 43 Is Essential for Neutrophil Recruitment during Intestinal Inflammation
Sina, C., Gavrilova, O., Förster, M., Till, A., Derer, S., Hildebrand, F., Raabe, B., Chalaris, A., Scheller, J., Rehmann, A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900063 · Cited by 376
Bodily, K. D., Fletcher, J. G., Solem, C. A., Johnson, C. D., Fidler, J. L., Barlow, J. M., Bruesewitz, M. R., McCollough, C. H., Sandborn, W. J., Loftus, E. V., et al. (2006) · Radiology · doi:10.1148/radiol.2382041159 · Cited by 363
Ulbrich, H., Eriksson, E. E., & Lindbom, L. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.10.004 · Cited by 354
Therapeutic antagonists and conformational regulation of integrin function
Shimaoka, M., & Springer, T. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1174 · Cited by 349
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Leukocyte Trafficking to the Small Intestine and Colon
Habtezion, A., Nguyen, L. P., Hadeiba, H., & Butcher, E. C. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.046 · Cited by 315
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease
Adams, D. H., & Eksteen, B. (2006) · Nature Reviews Immunology · doi:10.1038/nri1784 · Cited by 307
Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
Gorfu, G., Rivera-Nieves, J., & Ley, K. (2009) · Current Molecular Medicine · doi:10.2174/156652409789105525 · Cited by 292
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Mitroulis, I., Alexaki, V. I., Kourtzelis, I., Ziogas, A., Hajishengallis, G., & Chavakis, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.008 · Cited by 283
Barnes, P. J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1524 · Cited by 280
Biologic Therapy for Inflammatory Bowel Disease
Ardizzone, S., & Bianchi Porro, G. (2005) · Drugs · doi:10.2165/00003495-200565160-00002 · Cited by 280
Design of effective immunotherapy for human autoimmunity
Feldmann, M., & Steinman, L. (2005) · Nature · doi:10.1038/nature03727 · Cited by 277
α4Integrins as Therapeutic Targets in Autoimmune Disease
von Andrian, U. H., & Engelhardt, B. (2003) · New England Journal of Medicine · doi:10.1056/nejme020157 · Cited by 276
Treatment of inflammatory bowel disease: A review of medical therapy
Kozuch, P. L., & Hanauer, S. B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.354 · Cited by 261
Immune dysfunction in inflammatory bowel disease
Neuman, M. G. (2007) · Translational Research · doi:10.1016/j.trsl.2006.11.009 · Cited by 255
Recent understanding of IBD pathogenesis: Implications for future therapies
Kucharzik, T., Maaser, C., Lügering, A., Kagnoff, M., Mayer, L., Targan, S., & Domschke, W. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000235827.21778.d5 · Cited by 254
Celiac disease: From pathophysiology to treatment
Parzanese, I., Qehajaj, D., Patrinicola, F., Aralica, M., Chiriva-Internati, M., Stifter, S., Elli, L., & Grizzi, F. (2017) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v8.i2.27 · Cited by 253
Elkins, J., Veltkamp, R., Montaner, J., Johnston, S. C., Singhal, A. B., Becker, K., Lansberg, M. G., Tang, W., Chang, I., Muralidharan, K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30357-x · Cited by 224
Clark, M., Colombel, J.-F., Feagan, B. C., Fedorak, R. N., Hanauer, S. B., Kamm, M. A., Mayer, L., Regueiro, C., Rutgeerts, P., Sandborn, W. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.006 · Cited by 224
Self-citationKühl, A. A., Kakirman, H., Janotta, M., Dreher, S., Cremer, P., Pawlowski, N. N., Loddenkemper, C., Heimesaat, M. M., Grollich, K., Zeitz, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.073 · Cited by 187
Swanson, P. A., Hart, G. T., Russo, M. V., Nayak, D., Yazew, T., Peña, M., Khan, S. M., Janse, C. J., Pierce, S. K., & McGavern, D. B. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1006022 · Cited by 125
Lymphocyte homing to the gut: attraction, adhesion, and commitment
Salmi, M., & Jalkanen, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00285.x · Cited by 103
Resolution of inflammation in inflammatory bowel disease
Rogler, G. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30031-6 · Cited by 79
De Tena, J. G., Manzano, L., Leal, J. C., Antonio, E. S., Sualdea, V., & Álvarez-Mon, M. (2004) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000019784.20191.7f · Cited by 59
Metadata
- Authors
- Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-02
- Volume
- 348
- Issue
- 1
- Pages
- 24-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138223843
- Cited by
- 808
- References
- 23
- FWCI
- 43.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.